What Happens When You Stop Taking a GLP-1

By Wellness Wire Editorial

GLP-1 medications such as semaglutide (sold as Wegovy and Ozempic) and tirzepatide (sold as Zepbound and Mounjaro) have helped many people lose a meaningful amount of weight. A natural question follows close behind: what happens if you stop? The short version, based on the clinical trials done so far, is that most people regain a large share of the weight they lost, and some of the linked health improvements drift back too. Increasingly, researchers frame this not as a willpower problem but as the expected behavior of a chronic condition.

The short answer

In the studies that have followed people after they came off these drugs, weight tends to return. How much, and how fast, varies a great deal from person to person — some hold onto most of their loss, others regain nearly all of it. But on average, the direction is clear, and the same pattern shows up across different GLP-1 medications. Alongside the weight, several of the benefits that came with it — such as improvements in blood pressure and cholesterol — also tend to move back toward where they started.

What the trials actually found

The most-cited figures come from the STEP 1 trial and its extension. On average, participants had lost 17.3% of their body weight after 68 weeks on once-weekly semaglutide 2.4 mg. When treatment stopped, the weight began coming back: by week 120 — a year after the last dose — they had regained an average of 11.6 percentage points, leaving a net loss of about 5.6% from where they started. In plain terms, roughly two-thirds of the lost weight had returned within a year. It is worth knowing that this follow-up tracked 327 people who were simply observed after stopping — not a randomized withdrawal comparison like the trials below — and the spread was wide (the average regain carried a standard deviation of 7.7 points), so individual experiences ranged widely.

A more rigorous design tested the same question directly. In STEP 4, everyone first spent 20 weeks on semaglutide, then was randomly assigned either to keep taking it or to switch to a placebo. Over the following weeks, those who continued lost a further 7.9% of their body weight, while those switched to placebo regained 6.9% — a gap of about 14.8 percentage points between staying on and coming off (95% CI −16.0 to −13.5; P<.001). Because the two groups differed only in whether they kept taking the drug, this isolates the effect of stopping.

This is not unique to semaglutide. SURMOUNT-4 ran the same kind of test with tirzepatide. After a 36-week lead-in that produced an average 20.9% weight loss, people randomly switched to placebo regained 14.0% of their body weight, while those who stayed on the drug lost an additional 5.5% — a difference of 19.4 percentage points (95% CI −21.2 to −17.7; P<.001). In other words, regain after stopping appears to be a shared feature of this class of medication, not a quirk of one brand.

" Across different drugs and study designs, the pattern rhymes: stay on, and the loss largely holds; come off, and much of it returns.

Why the weight comes back

The trial investigators describe their findings as confirming the chronicity of obesity — the idea that it behaves like a long-term, relapsing condition rather than a problem that is fixed once and stays fixed. GLP-1 medications work while they are being taken; when they are withdrawn, the biological pressures that favored weight gain reassert themselves. Seen this way, regaining weight after stopping is closer to what happens when blood-pressure medication is stopped and blood pressure climbs again than it is to a lapse in discipline.

There is also a rough relationship between how much you lose and how much can come back. A 2025 systematic review pooling 36 studies concluded that regain after stopping anti-obesity drugs is drug-dependent and tends to scale with the size of the initial loss, with GLP-1 receptor agonists — semaglutide showing the largest rebound in that analysis — producing more regain than older agents such as orlistat. That review was published in a lower-tier journal, so it is best read as directional support for a commonsense pattern: the more dramatic the loss, the more weight there is to regain. The STEP and SURMOUNT trials remain the stronger evidence.

Real life can look different

The headline trial numbers describe stopping cold and doing nothing else — which is not how most people actually leave these medications. A real-world analysis from the Cleveland Clinic followed 7,938 adults and found a gentler picture. Among those treated for obesity, the group had lost about 8.4% of their weight before stopping and, on average, regained only around 0.5% in the year afterward. Just over half (55%) gained at least some weight back, while 45% maintained their loss or kept losing. The researchers attributed the smaller-than-trial regain largely to what patients did next: about 20% restarted the medication and 27% switched to another obesity treatment.

This cuts both ways, and it is worth being honest about the uncertainty. Real-world weight loss while on the drug is often smaller than in tightly controlled trials, and real-world regain after stopping can also be smaller — because people restart, switch agents, or lean on other support rather than stopping abruptly. It is also worth noting that most of this evidence only extends about a year past stopping. Whether weight eventually returns fully to baseline, levels off, or overshoots beyond one year is not well established from the studies available.

If you're thinking about stopping

The practical takeaway from the researchers themselves is reassuring in one specific way: if the weight returns after you stop, that is the expected physiological response, not a sign of personal failure. Durable weight maintenance, the trial authors conclude, generally requires ongoing treatment or another deliberate maintenance strategy. A few things are worth keeping in mind as you talk it through with a professional:

• The averages are not a forecast for you. Every headline figure is a group mean with wide variation — some people keep most of their loss, others regain all of it.
• Stopping and doing nothing is the scenario most likely to resemble the trials' larger regain numbers.
• Restarting the medication, switching to another treatment, or adding structured lifestyle support are among the reasons real-world outcomes can look milder.
• Weight is not the only thing that can drift back. In the STEP 1 extension, blood pressure and most cholesterol measures moved back toward their starting points once treatment stopped, though a marker of blood sugar (HbA1c) held onto some improvement.
• The longer-term picture beyond about a year off treatment simply isn't well mapped yet.

None of this means these medications don't work — the trials show they clearly do, for as long as they are taken. It means the decision to stop is worth planning, not improvising. If you are considering coming off a GLP-1, the most useful next step is a conversation with a licensed clinician who knows your history and can help you weigh the options.

1. 01
   Wilding JPH et al., STEP 1 trial extension, Diabetes, Obesity and Metabolism, 2022 pmc.ncbi.nlm.nih.gov ↗

   Off-treatment follow-up of 327 participants; ~two-thirds of lost weight regained a year after stopping semaglutide, with cardiometabolic markers drifting back toward baseline.
2. 02
   Rubino D et al., STEP 4, JAMA, 2021 pubmed.ncbi.nlm.nih.gov ↗

   Randomized withdrawal trial; placebo-switched group regained 6.9% while continued semaglutide lost a further 7.9% (−14.8 percentage-point difference, 95% CI −16.0 to −13.5).
3. 03
   Aronne LJ et al., SURMOUNT-4, JAMA, 2024 jamanetwork.com ↗

   Tirzepatide randomized withdrawal trial; placebo-switched group regained 14.0% versus continued treatment (−19.4% difference, 95% CI −21.2 to −17.7) after a 20.9% lead-in loss.
4. 04
   Gasoyan H et al. (Cleveland Clinic), Diabetes, Obesity and Metabolism, 2026 newsroom.clevelandclinic.org ↗

   Real-world cohort of 7,938 adults; smaller regain (~0.5% in the obesity group) partly because many patients restarted (20%) or switched (27%) therapy.
5. 05
   Kolli RT et al., Cureus, 2025 pmc.ncbi.nlm.nih.gov ↗

   Systematic review/meta-analysis of 36 studies; regain after stopping is drug-dependent and scales with initial loss, semaglutide showing the largest rebound. Lower-tier journal — treat as directional support.